

# BIOCARTIS GROUP NV

ISIN: BE0974281132 WKN: - Asset Class: **Stock**

## Company

2023/09/22 17:35:06



Price

**0.29** EUR

Difference 1.05%(0.00)



## Contact Details

BIOCARTIS GROUP NV Tel: +32-1-563-26-00  
 -- Fax: +  
 Generaal de Wittelaan Web:  
 11B <http://www.biocartisgroupnv.be>  
 2800 Mechelen E-mail: [info@biocartisgroupnv.be](mailto:info@biocartisgroupnv.be)

## Company Profile

Biocartis Group NV engages in the development of personalized medicine for patients around the world. It also focuses on developing and commercializing oncology tests. The company was founded by Philippe Renaud, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	65,159,000		92,980,000		158,290,000	
Common stock capital		931,000		575,000		575,000
Fixed assets	49,118,000		49,500,000		52,227,000	
Equity capital of a company		-30,284,000		-33,897,000		36,824,000
Cash and cash equivalents	26,125,000		53,522,000		123,668,000	
Accrued liabilities		204,000		75,000		0
Other assets	-		-		-	
Current liabilities		42,449,000		33,705,000		29,445,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		102,112,000		142,672,000		144,248,000
Different income		-		-		-
Other liabilities		149,000		313,000		363,000
Total assets	114,277,000	114,277,000	142,480,000	142,480,000	210,517,000	210,517,000

## Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	526	619	484
Equity ratio	-26.50%	-23.79%	17.49%
Debt-equity ratio	-477.35%	-520.33%	471.68%

## Others

	2022	2021	2020
Tax Expense Rate	0.37%	0.34%	0.36%

# BIOCARTIS GROUP NV

ISIN: BE0974281132 WKN: - Asset Class: **Stock**

## Income statement

	2022	2021	2020
Turnover	57,481,000	48,269,000	43,128,000
Net income	-65,381,000	-71,472,000	-62,934,000
EBIT	-43,558,000	-61,568,000	-48,061,000
Operating income before taxes	-64,737,000	-71,056,000	-62,630,000
Cash Flow	-44,922,000	-65,824,000	-39,304,000
Net interest income	-21,179,000	-9,488,000	-14,569,000
Research and development expenses	35,116,000	43,946,000	40,927,000
Income taxes	-240,000	-243,000	-228,000
Result from investments in subsidiaries, associates and other	-884,000	-659,000	-532,000
Revenues per employee	109,279	77,979	89,107

## Board of Directors

Herman Verrelst	Chairman of Supervisory Board
Bryan DeChairo	Member of Supervisory Board
Christian Reinaudo	Member of Supervisory Board
Christine Kuslich	Member of Supervisory Board
Ann-Christine M. Sundell	Member of Supervisory Board
Luc Gijzens	Member of Supervisory Board

## Members of Management Board

Roger Moody	Chairman of Managing Board
George Cardoza	Member of Executive Committee
Piet Houwen	Member of Executive Committee